Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gel could outperform standard therapy for kidney disease

NCT ID NCT05696613

Disease control Sponsor: Cerium Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial is testing a new gel called SNP-ACTH (1-39) against the standard drug rituximab in 148 adults with primary membranous nephropathy, a rare kidney condition. The goal is to see if the gel can better reduce protein in the urine and protect kidney function over 24 months. Participants are at high risk of kidney decline and will be randomly assigned to one of the two treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SNP-ACTH (1-39) Gel
What this could lead to
If this works, it could offer a new treatment option for people with a rare kidney disease, potentially reducing protein leakage and preserving kidney function better than current therapies.
What could go wrong
This is still an early-stage Phase 3 trial with only 148 participants, so results may not apply to everyone. The gel may not prove superior to rituximab, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 148 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Biopsy-proven membranous glomerulonephritis or a diagnosis of MN in patients with Nephrotic Syndrome and a positive anti PLA2R antibody test. * Patients classified to be at a High Risk for progressive loss of kidney function, as defined by Kidney Disease Improving Global Outcomes (KDIGO) 2021-Glomerular Diseases Guideline. * eGFR by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula ≥40 mL/min/1.73 m\^2 * Patients who have had CR or PR in response to immunosuppressive therapy, but then relapsed can participate in the study if it has been more than 3 months since their last dose of high dose glucocorticoids, calcineurin inhibitors or mycophenolate mofetil * Patients who have had CR or PR in response to IS therapy, but then relapsed can participate in the study if it has been more than 6 months since their last dose of chlorambucil or cyclophosphamide * Patients who have had CR or PR in response to immunosuppressive therapy, but then relapsed can participate in the study if it has been more than 12 months since their last dose of rituximab. * Life expectancy \> 24 months. * Other inclusion criteria may apply. Exclusion Criteria: * Secondary membranous nephropathy as defined by history, physical exam, kidney biopsy results or serologies. * Patients who have had a ≥ 50% reduction in serum titers of PLA2R auto-antibody within 1 year before screening. * Type 1 or 2 diabetes mellitus * Patients who must be initiated on drugs likely to affect renal function if not properly dosed. * Surgery within 1 month of study entry * History of sensitivity to proteins of porcine origin. * Other exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary membranous nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic membranous glomerulonephritis kidney disorder membranous glomerulonephritis nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary membranous nephropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    31 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AIIMS

    RECRUITING

    Raipur, Chhattisgarh, 492099, India

  • Academic Medical Research Institute

    RECRUITING

    Los Angeles, California, 90022, United States

  • Apex Hospitals

    RECRUITING

    Jaipur, Rajasthan, 302017, India

  • Center for Advanced Kidney Research, PLC

    RECRUITING

    Saint Clair Shores, Michigan, 48080, United States

  • Costal Medical Research

    RECRUITING

    Brunswick, Georgia, 31520, United States

  • Fides Clinical Research

    RECRUITING

    Atlanta, Georgia, 30342, United States

  • Galaxy Hospital

    RECRUITING

    Varanasi, Uttar Pradesh, 221010, India

  • Genesis Clinical Research

    RECRUITING

    Tampa, Florida, 33603, United States

  • Insight Hospital and Medical Center Chicago

    RECRUITING

    Chicago, Illinois, 60615, United States

  • KLE Hospital

    RECRUITING

    Belagavi, Karnataka, 590010, India

  • Muljibhai Patel Urological Hospital

    RECRUITING

    Nadiād, Gujarat, India

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

  • Nephrology Associates of Northern Virginia

    RECRUITING

    Fairfax, Virginia, 22033, United States

  • North America Research Institute

    RECRUITING

    San Dimas, California, 91773, United States

  • P&I Clinical Research LLC

    RECRUITING

    Lufkin, Texas, 75904, United States

  • PGIMER

    RECRUITING

    Chandigarh, Punjab, 160012, India

  • Prolato Clinical Research Center

    RECRUITING

    Houston, Texas, 77054, United States

  • RecioMed Clinical Research Network, Inc.

    RECRUITING

    Boynton Beach, Florida, 33472, United States

  • Regional Kidney Wellness Centre

    RECRUITING

    Brampton, Ontario, L6T 0H9, Canada

  • Reliant Medical Research, LLC

    RECRUITING

    Miami, Florida, 33165, United States

  • SMS Medical College and Hospital

    RECRUITING

    Jaipur, Rajasthan, 302004, India

  • Saraswati Kidney Care Center

    RECRUITING

    Nagpur, Maharashtra, 440015, India

  • Sir Ganga Ram Hospital

    RECRUITING

    New Delhi, National Capital Territory of Delhi, 10060, India

  • South Florida Nephrology Research

    RECRUITING

    Coral Springs, Florida, 33071, United States

  • Therafirst Medical Center

    RECRUITING

    Fort Lauderdale, Florida, 33308, United States

  • University of Iowa

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • University of Virginia

    RECRUITING

    Charlottesville, Virginia, 22908, United States

  • Valiance Clinical Research

    RECRUITING

    Tarzana, California, 91356, United States

  • Vedanta Hospitals

    RECRUITING

    Guntur, Andhra Pradesh, 522001, India

  • Vijaya Super Speciality Hospital

    RECRUITING

    Nellore, Andhra Pradesh, 524001, India

  • Vista Health Research, LLC

    RECRUITING

    Miami, Florida, 33176, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.